{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T23:24:46Z","timestamp":1775172286271,"version":"3.50.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,15]]},"DOI":"10.1093\/cid\/cix015","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T13:27:11Z","timestamp":1485782831000},"page":"1006-1016","source":"Crossref","is-referenced-by-count":39,"title":["Virological Outcomes of Second-line Protease Inhibitor\u2013Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis"],"prefix":"10.1093","volume":"64","author":[{"given":"Dami","family":"Collier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collins","family":"Iwuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Derache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulio","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nonhlanhla","family":"Okesola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Dabis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"key\n\t\t\t\t20170522104603_CIT0001","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/civ556","article-title":"Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0002","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0003","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"PharmAccess African Studies to Evaluate Resistance (PASER)","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0004","doi-asserted-by":"crossref","first-page":"e72152","DOI":"10.1371\/journal.pone.0072152","article-title":"High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa","volume":"8","author":"Southern African Treatment and Resistance Network","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0005","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3018(16)00016-3","article-title":"The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study","volume":"3","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20170522104603_CIT0006","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0007","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","article-title":"High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa","volume":"53","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522104603_CIT0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/infdis\/jit411","article-title":"Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0009","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3851\/IMP1819","article-title":"Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa","volume":"16","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522104603_CIT0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0b013e3182615ad1","article-title":"Second-line antiretroviral therapy: long-term outcomes in South Africa","volume":"61","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522104603_CIT0011","doi-asserted-by":"crossref","first-page":"e58526","DOI":"10.1371\/journal.pone.0058526","article-title":"Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0012","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","article-title":"Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa","volume":"205","author":"PharmAccess African Studies to Evaluate Resistance (PASER)","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0013","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"EARNEST Trial Team","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522104603_CIT0014","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/QAD.0000000000000709","article-title":"Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa","volume":"29","author":"2LADY Study Group","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0015","doi-asserted-by":"crossref","first-page":"e0140623","DOI":"10.1371\/journal.pone.0140623","article-title":"Correction: raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir\/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection","volume":"10","author":"SECOND-LINE","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0016","first-page":"232","article-title":"Second-line treatment in sub-Saharan Africa: week 144 follow-up of the earnest trial","volume":"23","year":"2015","journal-title":"Top Antiviral Med"},{"key":"key\n\t\t\t\t20170522104603_CIT0017","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","article-title":"Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522104603_CIT0019","doi-asserted-by":"crossref","first-page":"e28691","DOI":"10.1371\/journal.pone.0028691","article-title":"Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1745-6215-14-230","article-title":"Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (treatment as prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial","volume":"14","author":"ANRS 12249 TasP Study Group","year":"2013","journal-title":"Trials"},{"key":"key\n\t\t\t\t20170522104603_CIT0021","volume-title":"The 2013 National Antenatal Sentinel HIV Prevalence Survey South Africa","author":"National Department of Health","year":"2015"},{"key":"key\n\t\t\t\t20170522104603_CIT0022","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ije\/dyp402","article-title":"Cohort profile: Hlabisa HIV treatment and care programme","volume":"40","year":"2011","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20170522104603_CIT0023","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1128\/JCM.01516-12","article-title":"Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes","volume":"50","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522104603_CIT0024","article-title":"An affordable HIV-1 drug resistance monitoring method for resource limited settings","year":"2014","journal-title":"J Vis Exp"},{"key":"key\n\t\t\t\t20170522104603_CIT0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20170522104603_CIT0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"key\n\t\t\t\t20170522104603_CIT0027","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","author":"SECOND-LINE Study Group","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522104603_CIT0028","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa","volume":"49","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0029","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/cit933","article-title":"High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy","volume":"58","author":"DART Virology Group and Trial Team","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0030","volume-title":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision","author":"World Health Organization","year":"2010"},{"key":"key\n\t\t\t\t20170522104603_CIT0031","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/AAC.00461-06","article-title":"Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522104603_CIT0032","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522104603_CIT0033","volume-title":"National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults","author":"National Department of Health","year":": 2014"},{"key":"key\n\t\t\t\t20170522104603_CIT0034","doi-asserted-by":"crossref","first-page":"e44793","DOI":"10.1371\/journal.pone.0044793","article-title":"Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0036","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5588\/ijtld.13.0492","article-title":"Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa","volume":"18","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0037","first-page":"16","article-title":"Does a universal test and treat strategy impact ART adherence in rural South Africa? ANRS 12249 TasP cluster-randomized trial","volume":"18","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20170522104603_CIT0038","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0039","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/QAD.0000000000001033","article-title":"Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing","volume":"30","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0040","doi-asserted-by":"crossref","first-page":"e32144","DOI":"10.1371\/journal.pone.0032144","article-title":"Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522104603_CIT0041","first-page":"769627","article-title":"Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir\/r-containing antiretroviral therapy in South Africa","volume":"2011","year":"2011","journal-title":"AIDS Res Treat"},{"key":"key\n\t\t\t\t20170522104603_CIT0042","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jiw219","article-title":"Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa","volume":"214","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0043","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human immunodeficiency virus Gag and protease: partners in resistance","volume":"9","year":"2012","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20170522104603_CIT0044","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/QAD.0b013e3283398216","article-title":"Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522104603_CIT0045","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/JVI.02356-08","article-title":"Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1","volume":"83","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170522104603_CIT0046","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dku296","article-title":"Phenotypic characterization of virological failure following lopinavir\/ritonavir monotherapy using full-length gag-protease genes","volume":"69","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522104603_CIT0047","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dku365","article-title":"HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir\/ritonavir","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522104603_CIT0048","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","year":"2013","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170522104603_CIT0049","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0000000000000568","article-title":"Single genome analysis for the detection of linked multiclass drug resistance mutations in HIV-1-infected children after failure of protease inhibitor-based first-line therapy","volume":"69","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522104603_CIT0050","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1089\/aid.2014.0349","article-title":"Genetic changes in HIV-1 Gag-protease associated with protease inhibitor-based therapy failure in pediatric patients","volume":"31","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170522104603_CIT0051","article-title":"Occult drug resistance to thymidine analogues and multidrug resistant HIV-1 following failure of first line tenofovir-based antiretroviral regimens in sub-Saharan Africa: a retrospective multi-centre cohort study","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522104603_CIT0052","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522104603_CIT0053","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis to ART","author":"World Health Organization"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/64\/8\/1006\/17353063\/cix015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T19:47:01Z","timestamp":1503604021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cix015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,3,13]]},"published-print":{"date-parts":[[2017,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix015","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}